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Key Points
• A 6-year overall survival
of 61% was observed
in leukodystrophy pa-
tients after cord blood
transplantation.
•Mismatched cord blood
donors, symptomatic
disease, and lower PS
before cord blood
transplantation were
predictors of lower
survival.
Leukodystrophies (LD) are devastating inherited disorders leading to rapid neurological
deterioration and premature death. Hematopoietic stem cell transplantation (HSCT) can
halt disease progression for selected LD. Cord blood is a common donor source for
transplantation of these patients because it is rapidly available and can be used without full
HLA matching. However, precise recommendations allowing care providers to identify
patients who benefit fromHSCT are lacking. In this study, we define risk factors and describe
the early and late outcomes of 169 patients with globoid cell leukodystrophy, X-linked
adrenoleukodystrophy, and metachromatic leukodystrophy undergoing cord blood trans-
plantation (CBT) at an European Society for Blood and Marrow Transplantation center or at
Duke University Medical Center from 1996 to 2013. Factors associated with higher overall
survival (OS) included presymptomatic status (77% vs 49%; P5 .006), well-matched (#1 HLA
mismatch) CB units (71% vs 54%; P5 .009), and performance status (PS) of.80 vs,60 or 60
to 80 (69% vs 32% and 55%, respectively; P5 .003). For patients with PS#60 (n5 20) or 60 to
80 (n 5 24) pre-CBT, only 4 (9%) showed improvement. Of the survivors with PS .80 pre-
CBT, 50% remained stable, 20% declined to 60 to 80, and 30% to,60. Overall, an encouraging
OS was found for LD patients after CBT, especially for those who are presymptomatic before
CBT and received adequately dosed grafts. Early identification and fast referral to a
specialized center may lead to earlier treatment and, subsequently, to improved outcomes.
Introduction
Leukodystrophies (LD) are a heterozygous group of rare inherited diseases that affect the development
and maintenance of brain myelination. Although the age of onset and clinical course varies among this
group of diseases, all inherited leukodystrophies are characterized by progressive neurological
deterioration and premature death. They often arise from either a lysosomal storage disease
(LSD), such as metachromatic leukodystrophy (MLD) and globoid cell leukodystrophy–Krabbe
disease (GLD), or a peroxisomal disorder such as X-linked adrenoleukodystrophy (X-ALD).
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Hematopoietic stem cell transplantation (HSCT) has been
shown to arrest or slow disease progression for MLD, GLD, and
X-ALD, particularly when performed in presymptomatic patients
or patients with early-stage disease.1,2 In patients with a LSD,
HSCT works through engraftment of donor cells that can cross
the blood-brain barrier, providing a source of cellular enzyme
replacement through cross-correction of host cells by enzyme-
replete donor cells.3 Conversely, in X-ALD, in which the
defected protein is not an enzyme but a transporter protein,
the exact mechanism of action of HSCT is not completely
understood.
Umbilical cord blood (CB), related or unrelated, provides an
alternative source of hematopoietic stem cells for transplantation.
After over 2 decades of experience, researchers have well
described the benefits of CB. Particularly relevant to patients with
LDs, a rapidly progressive disease, CB is readily available, allowing
for shorter time to transplant. In patients with LDs, the early
outcomes of umbilical cord blood transplantation (CBT) have been
described.4-10 These studies suggest that CBT is most beneficial
when performed early, preferably before the onset of symptoms.
Although it would be ideal to compare the early and late outcomes
on the basis of cell source such as those performed for Hurler’s
disease,11 this was not possible because of the very limited
numbers of patients receiving other cell sources, leading us to focus
on cord blood only. In this report, we describe the results of a
collaboration among Eurocord, the European Society for Blood and
Marrow Transplantation (EBMT), and Duke University to define risk
factors and describe the early and late outcomes in a large cohort of
patients with LDs (MLD, GLD, and X-ALD) treated after CBT.
Patients and methods
Data collection and patients
In this retrospective, multicenter study, patients (children and adults)
with leukodystrophies (MLD, GLD, or X-ALD) who received related or
unrelated donor CBT between September 1996 and August 2013
were included. Data were collected from the Eurocord Registry from
EBMT centers through standardized questionnaires that included
information about the patients, donors, diseases, and transplant
outcomes. Data on patients from Duke University were collected
through similar questionnaires as those used by the Eurocord-EBMT.
Missing data were completed by institutional data managers. An
additional follow-up questionnaire was developed for long-term
outcomes and sent out to participating centers. Symptomatic patients
were categorized into disease subtype on the basis of age of onset of
symptoms; presymptomatic patients were categorized on the basis of
age of onset of the index case in the family. MLD patients were
classified as late infantile (0-4 years), early juvenile (4-6 years), late
juvenile (6-16 years), or adult (.16 years). Patients with GLD were
classified as early infantile (,6 months), late infantile (6-11 months),
juvenile (1-16 years), or adult (.16 years). Patients with ALD were
classified as childhood (0-10 years), adolescent (10-18 years), or adult
(.18 years). All patients with ALD showed evident cerebral disease on
magnetic resonance imaging (MRI) at time of transplantation. Part of
this cohort (n5 70) has been reported in previous studies.5,12,13 This
study was performed in agreement with the Helsinki Declaration of
1975, revised in 2008. All patients or their legal representatives gave
informed consent. Eurocord and theWorking Party for Inborn Errors of
EBMT approved the European part of this study. In the United States,
approval was given by the institutional review board of Duke University.
Outcomes of interest
Outcomes of interest were overall survival (OS) and event-free
survival (EFS). OS was defined as the time from transplantation
to death. EFS was defined as time from transplantation to
last assessment without an event. Events were considered to be
autologous reconstitution (documentation of ,5% donor-derived
engraftment), graft failure (lack of neutrophil recovery or transient
engraftment of donor cells after transplantation, requirement for a
second transplant, or both), or death. All surviving patients were
censored at date of last contact.
Other outcomes of interest were neutrophil recovery, defined as
the first day of achieving a neutrophil count of $0.5 3 109/L for
3 consecutive days, incidence of acute and chronic graft- versus-
host disease (GVHD), donor chimerism, enzyme level (arylsulfa-
tase A and galactocerebrosidase tested in blood cell lysates for
MLD and GLD, respectively), very long chain fatty acid (VLCFA)
level tested in blood cell lysates for X-ALD, and long-term
outcomes. Acute GVHD grade II-IV at day 100 was diagnosed
and graded according to published criteria.14 Chronic GVHD at
5 years was graded according to standard criteria15 and
evaluated in patients who survived at least 100 days with
sustained engraftment. Long-term outcomes included perfor-
mance score (PS), either Lansky or Karnofsky on the basis of
patient age, at 12 months and at latest follow-up time point;
overall disease status (symptomatic, defined as clinical disease
according to the local clinician, or presymptomatic, defined as no
clinical disease according to the local clinician); descriptive
neurological status (presence and severity of peripheral neurop-
athy, presence of seizures, mental development [tested by
Bayley Scales of Infant Development, Stanford-Binet Intelligence
Scale, Wechsler Preschool and Primary Scale of Intelligence—
Revised, Wechsler Intelligence Scale for Children—III]), vision
(normal, low: ,20/60; blind: ,20/400), hearing (normal,
,25 dB hearing loss; mild hearing loss, 26-55 dB; severe
hearing loss, .56 dB), and cerebral atrophy observed by
magnetic resonance imaging [MRI]); incontinence; independence
in daily living; school attendance; and school performance.
Furthermore, gall bladder disease was registered for patients with
MLD16,17 and adrenal insufficiency for patients with X-ALD (as
reported by local clinicians).
Statistical analysis
Probabilities of EFS and OS were calculated using the Kaplan-Meier
estimate; the 2-sided log-rank testwas used for univariate comparisons.
Cumulative incidence curves were created for neutrophil recovery;
acute GVHD and chronic GVHD were analyzed in a competing risk
setting. In univariate analyses, we considered variables associated with
the recipient (median age at transplant, median weight at time of
transplantation, sex, pretransplant cytomegalovirus serology status),
the disease (type of diagnosis, and median interval time from diagnosis
or [in ALD only] first abnormal brain MRI to transplant), the cord blood
unit (HLA disparity, and median collected and infused total nucleated
cells andCD341 cell doses), and the transplant (year of transplant, use
of myeloablation, antithymocyte globulin [ATG], and the type of GVHD
prophylaxis). Factors associated with P ,.10 in univariate analysis
50 van den BROEK et al 9 JANUARY 2018 x VOLUME 2, NUMBER 1
D
ow
nloaded from
 https://ashpublications.org/bloodadvances/article-pdf/2/1/49/879739/advances010645.pdf by U
N
IVER
SITEIT ZIEKEN
H
U
IS user on 03 August 2020
and factors considered relevant risk factors were included in
multivariate analyses, using Cox proportional hazards for EFS, OS,
neutrophil recovery, and GVHD. Subsequently, a stepwise regression
analysis was performed using a threshold of 0.05. All statistical
analyses were performed using SPSS (version 19; SPSS Inc.,
Chicago, IL) and R (version 3.32.0; R Foundation for Statistical
Computing, Vienna, Austria) software packages. Figures were created
with GraphPad Prism (version 7.02; GraphPad Software, La Jolla, CA).
Results
Patient, donor, and transplant characteristics
One hundred and sixty-nine patients were included: 66 MLD,
47 GLD, and 56 X-ALD. Overall, the median age at time of CBT was
5.1 years (range: 0.1-43.3); patients with X-ALD were the oldest,
with a median age of 8.2 years, followed by MLD (4.3 years) and
GLD (0.6 years). The majority of the patients received myeloablative
conditioning (97%) with busulfan (Bu)/cyclophosphamide (Cy) as
the most frequent regimen (83.4%). Ninety-two percent received a
single CB graft, with a median total nucleated cell dose (TNC) of
5.7 3 107 cells/kg and a median CD341 dose of 2.1 3 105/kg.
A cyclosporine-based regimen was used as GVHD prophylaxis in
97% of the patients, and 96% received ATG as serotherapy. Median
follow-up for survivors was 76 months (range: 3-211). Patient, donor,
and transplant characteristics are shown in Table 1.
Table 1. Baseline patient, donor, and transplantation characteristics
Baseline characteristics*
Characteristics n %
Patient
Overall 169
MLD 66 39.1
GLD 47 27.8
X-ALD 56 33.1
Child (,18 y)/adult 161/8 95.3/4.7
Sex (male/female) 118/51 69.8/30.2
Cytomegalovirus serology (negative) 127 77.9
Median Range
Weight, kg 19.5 2.74-75.0
Age at SCT, y
Overall 5.1 0.1-43.3
MLD 4.3 0.1-22.7
GLD 0.6 0.1-16.7
X-ALD 8.2 2.4-43.3
Interval diagnosis-transplant, mo
Overall 2.8 0.6-147.9
MLD 3.0 0.6-70.3
GLD 1.6 0.6-60.0
X-ALD 5.4 0.6-147.9
Performance score pre-SCT
,60 29 19.6
60-80 29 19.6
.80 90 60.8
Donor n %
sCB 156 92.3
dCB 13 7.7
Unrelated/related 168/1 99.4/0.6
HLA matching
6/6 27 18.1
5/6 56 37.6
4/6 65 43.6
3/6 1 0.7
CB cell dose Median Range
Collected NC, 3107/kg 8.0 2.1-67.2
Collected CD341, 3105/kg 2.7 0.01-28.5
Infused NC, 3107/kg 5.7 1.2-50.3
Infused CD341, 3105/kg 2.1 0.01-32.4
Transplantation n %
Conditioning regimen
MAC 163 97
Bu/Cy/(TT) 135 (1)
Bu/Fluda/(Cy)(Mel)(TT) 9 (4)(3)(3)
Fluda/TT/Mel 3
Bu/Mel/other 1
TBI/Cy 4
Table 1. (continued)
Baseline characteristics*
Characteristics n %
RIC 5 3
Fluda/Mel 1
Mel/other 1
Fluda/other 2
Cy/Fluda/TBI 1
GVHD prophylaxes
CsA based 156 96.9
1steroids 34
1MMF 29
1Mtx 4
Tacrolimus-based 5 3.1
1MMF 4
1Mtx 1
Serotherapy (ATG before day 0) 162 96.4
Median Range
Year of HCT 2006 1996-2013
Follow-up post SCT,† mo 76.3 3.3-211
ATG, anti-thymocyte globulin; Bu, busalfan; CsA, cyclosporine; Cy, cyclophosphamide;
dCB, double cord blood; Fluda, fludarabine; MAC, myoablative conditioning; Mel,
melphalan; MMF, mofetil; Mtx, methotrexate; NC, neutrophil count; RIC, reduced intensity
conditioning; sCD, single cord blood; SCT, stem cell transplantation; TBI, total body
irradiation; TT, thiotepa.
*CB transplantation was performed in the following centers: Duke (102), Utrecht (11),
Marseille (6), Australia (6), Saudi Arabia (5), Madrid (4), Gent (4), Brussels (4), Paris (4),
Milano (2), Murcia (2), Barcelona (2), Montre´al (2), Budapest (2), Leiden (1), Leuven (1),
Jerusalem (1), Porto (1), Hannover (1), Lisboa (1), Berlin (1), Manchester (1), Antalya (1),
Poland (1), Nancy (1), Israel (1), and Bratislava (1).
†Median follow-up of survivors.
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Neutrophil and platelets recovery and chimerism
The cumulative incidence of neutrophil engraftment at day 60 was
86.3% (range: 81.2% to 91.7%; Table 2), with a median time to
engraftment of 21 days (range: 11-83). In univariate analysis,
factors associated with a higher probability of neutrophil recovery
included shorter interval between diagnosis and CBT (#2.84
months: 91.5%, vs .2.84 months: 80.4%; P 5 .01), higher
infused CD341 cell dose (#2.05 3 105/kg: 82.7%, vs .2.05 3
105/kg: 88.6%; P 5 .05), and higher infused TNC (#5.73 3
107/kg: 82.7%, vs .5.73 3 107/kg: 88.9%; P 5 .008). The
cumulative incidence of platelet recovery was 68 6 6% at day
180, and the median time to platelet recovery (.20 000/mL) was
52 days (range: 13-200 days). Twenty patients (12%) experi-
enced either autologous reconstitution (n 5 6; 3.5%) or
secondary graft failure (n 5 14; 8%) during the first 3 months
after CBT. Thirteen of these patients subsequently died because
of disease progression (n 5 3) or graft failure (n 5 10). Eight
patients received a second transplant using CB (n 5 5), peripheral
blood stem cells (n 5 1), or not specified (n 5 2) as the donor
source. Of these, 6 patients survived long term, and 2 died
(1 because of disease progression, and 1 transplant-related
mortality). One patient with autologous recovery survived long
term without a second transplant. Chimerism at day 100 was
available for 125 out of 148 engrafted patients. Full chimerism was
achieved in 104 (83.2%) of the patients, and mixed chimerism in
21 (16.8%). Chimerism at last assessment was available for all
100 survivors (full chimerism, n 5 87; mixed chimerism, n 5 13).
Of patients who were “alive and engrafted,” normal enzyme levels
were found in 94.8% and 96.6%, for MLD and GLD, respectively.
Acute and chronic GVHD
The cumulative incidence of acute GVHD grades II-IV and III-IV at day
100 was 35.3% 6 7%, and 20.2% 6 8% (Table 2), respectively.
Univariate analysis showed that a longer interval between diagnosis
and CBT was associated with a higher probability of acute GVHD
grade II-IV (47.6% for #2.84 and 25% for .2.84; P 5 .002). The
cumulative incidence of chronic GVHD at 5 years was 30.2% 6 5%
(15 extensive and 28 limited). In univariate analysis, higher PS at the
time of CBT was associated with a higher incidence of chronic GVHD
(12.1% for PS # 60, 20.8% for PS 60-80, and 41.6% for PS . 80;
P5 .009; 65%was limited chronic GVHD). Only 6 of the patients with
chronic GVHD and a lower PS before CBT (n5 2 for,60, and n5 4
for 60-80) were still alive at latest follow-up.
Table 2. Primary and secondary endpoints
Endpoints % Events, n
Primary
6-y OS overall 61
MLD 67
X-ALD 59
GLD 55
6-y EFS overall 59
MLD 66
X-ALD 56
GLD 53
Secondary
Neutrophil engraftment (day 60)* 86.3
Platelet engraftment (day 180)† 68
Graft failure (primary/secondary) 3.6/8.3 6/14
Chimerism (within 100 d)
Full donor 83.2 104
Mixed 16.8 21
CIF of acute GVHD
Stage II-IV 35.3 59
Stage III-IV 20.2 21
CIF of chronic GVHD at 5 y 30.2 44
Limited/extended 28/15
CIF, cumulative incidence function.
*Median, 21; range, 11-83.
†Median, 52; range, 13-200.
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Figure 1. Six-year overall and event-free survival. (A) OS. (B) EFS. (C) EFS per LD type. Events for EFS were considered to be autologous reconstitution, graft failure, or death.
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OS, EFS, and causes of death
The 1-year and 6-year OS among all patients was 736 3% and 61
6 4% (Figure 1A), respectively, with a median follow-up of 76
months (range: 12-211). Similar OS was observed for the 3 LD
types. Improved OS was observed in patients with late-onset
disease in MLD and early-onset disease in patients with GLD or
X-ALD (supplemental Figure 1), although this should be inter-
preted with caution because classification of patients might have
been based on an index case. In univariate analysis, several clinical
factors were associated with improved OS including recipients
of 5/6 or 6/6 HLA-matched grafts (71% vs 54% for 3-4/6
HLA-matched grafts; P 5 .009), absence of cerebral atrophy on
MRI prior to CBT (68% vs 35% for patients with cerebral atrophy;
P , .001), PS before CBT . 80 (69% in comparison with
55% and 32% for patients with PS 60-80 or ,60, respectively;
P 5 .003). Presymptomatic or mildly affected patients also
experienced higher OS than did symptomatic patients (77% vs
49%; P 5 .006). OS was not influenced by year of transplantation
(median 2006; 59 6 5% vs 63 6 7%; P 5 .44). Further analysis
revealed that differences in OS between presymptomatic and
symptomatic patients were most notable in GLD and X-ALD patients
(GLD: 78% vs 36%, P 5 .02; X-ALD: 88% vs 47%, P 5 .02; and
MLD 70% vs 62%, P5 .64). In multivariate analysis, recipients of 5/6
or 6/6 HLA-matched grafts (hazard ratio [HR], 1.8; 95%
confidence interval [CI], 1.0-3.3; P 5 .04) as well as pre-
symptomatic disease status (HR, 2.0; 95% CI, 1.0-3.7; P 5 .04)
were significantly associated with higher OS at 6 years.
In the overall cohort, the 1-year EFS was 72 6 4% and the 6-year
EFS 59 6 4% (Figure 1B). Although there was a trend toward
improved EFS for patients with presymptomatic disease and those
who received 5 or 6/6 HLA-matched grafts, no clinical factors were
significantly associated with EFS in multivariate analysis (Table 3).
Notably, presymptomatic GLD patients had significantly increased
EFS in comparison with that of symptomatic GLD patients (78% vs
32%; P 5 .009; Figure 2).
Sixty-nine patients died within 6 years after CBT (MLD n5 23; GLD
n 5 25; X-ALD n 5 21). Forty-three patients died of transplant-
related causes (infection: n 5 18; GVHD: n 5 9; pulmonary
disease: n 5 7; multisystem organ failure: n 5 4; or other: n 5 5)
and 21 from disease progression. Additional causes of death are
provided in supplemental Table 1.
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Figure 2. EFS for patients at time of CBT. EFS is given for presymptomatic (A) and symptomatic (B) patients. Events were considered to be autologous reconstitution,
graft failure, or death.
Table 3. Multivariate predictors of 6-year OS and EFS
6-year survival HR 95% CI P
OS
HLA 0-1 vs $2 HLA
mismatches
1.8 1.0-3.3 .04
Presymptomatic vs
symptomatic
2.0 1.0-3.7 .04
Collected TNC $ 5.0 3 105
vs collected TNC , 5.0 3 105
1.5 0.7-3.2 .34
EFS
HLA 0-1 vs $2 HLA
mismatches
1.7 1.0-2.9 .059
Presymptomatic vs
symptomatic
1.8 1.0-3.2 .057
Collected TNC $ 5.0 3 105
vs collected TNC
, 5.0 3 105
1.6 0.7-3.4 .227
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Functional and disease-related outcomes
To compare functional outcomes after CBT, we used the pre- and
posttransplant PS and retrospectively assigned disease status on
the basis of symptoms present at the time point of interest. Pre- and
posttransplant PS were available for 119 patients. Among survivors
with normal pretransplant functional status (PS . 80), 50% had a
PS . 80 at last follow-up (median 69 months; range: 12-211;
Figure 3), and the remaining showed a decline in PS to 60-80
(20%) or ,60 (30%). For patients with lower pretransplant PS
(#60, n 5 20; 60-80, n 5 24), only 4 patients demonstrated
improved PS after CBT and at last follow-up. When decline in PS
occurred after CBT, it most commonly occurred during the first year
and was stable afterwards (Figures 3 and 4). Changes in
performance scores according to LD type are shown in Figure 4.
In addition, changes in performance score according to the different
clinical phenotypes per LD can be found in supplemental Figure 2.
Data on disease-related outcomes was available for all patients
pre-CBT (n 5 169) and for 98 patients who survived more than 1
year post-CBT (Tables 4 and 5). In patients with enzyme testing
results post-CBT, 93% and 95% of patients for MLD and GLD,
respectively, achieved normal enzyme levels (arylsulfastase A or
galactocerebrosidase), according to local references. In patients
with LSDs (MLD and GLD), 40% and 18% of patients were
presymptomatic pre- and post-CBT, respectively (Table 4). Of the
presymptomatic patients, 62% remained without symptoms at last
follow-up. Vision and hearing stabilized or improved in the majority
of patients after CBT (94% and 96%, respectively). Seizures were
reported in 24% of patients post-CBT. Neuropathy, as detected
by clinical exam or symptoms, was absent or mild in 61.5% of
patients pre-CBT and remained stable or improved in 72% post-
CBT. Data on school performance were available for most patients
alive at latest follow-up post-CBT (81%). In this primarily pediatric
cohort, 28% were identified as having age-appropriate school
performance. Additional educational support was provided to
71% of patients with available data. Gallbladder disease was
observed in 12% (n 5 3) of patients with MLD after CBT. All 3
patients required cholecystectomy. Comparatively, patients with
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X-ALD appear to have better late outcomes (Table 5). Of
presymptomatic patients, 100% remained without symptoms at
last follow-up. Neuropathy was uncommon (absent or mild in 96%)
pre-CBT and remained stable in 89%. Although hearing was rarely
affected (96% with normal or mild hearing loss) and remained
stable or improved in 93%, vision was affected more often. Normal
vision was seen in 71% pre-CBT and worsened in 20% post-CBT.
Seizures were reported in 18% post-CBT. Almost all patients
(92.6%) experienced stable adrenal function. Data available on
school performance showed that 74% had age-appropriate
school performance; educational support was provided to 32%.
The most frequent interventions and complications after CBT were
G-tube placement (13 with MLD, 20 patients with GLD, and 9 with
X-ALD), followed by issues with dentition (9 with MLD, 14 with
GLD, and 2 with X-ALD) and surgery (9 MLD, 9 GLD, and 2 X-ALD).
Late pulmonary toxicity was seen in 16 patients (3 MLD, 4 GLD, and
9 X-ALD) and cardiac toxicity in 14 patients (5 MLD, 7 GLD, 2
X-ALD; supplemental Table 2).
Discussion
To the best of our knowledge, this retrospective study, spanning
over 20 years of clinical experience, is the largest to describe both
early and late outcomes after CBT in patients with leukodystro-
phies undergoing CBT. In this joint study of Eurocord, Inborn
Errors Working Party EBMT, and Duke University, we demonstrate
a promising 1-year and 6-year OS (73% and 61%, respectively)
and EFS (72% and 59%, respectively). Importantly, we ob-
served an OS at 6 years of nearly 80% in patients who were
presymptomatic at time of CBT. Furthermore, the majority of these
patients (53%) maintained a performance score.80 after CBT at
latest follow-up. This confirms previous smaller analyses6,18,19
showing that leukodystrophy patients transplanted prior to clinical
symptoms experience long-term survival while maintaining cogni-
tive and motor function, in comparison with symptomatic or
nontransplanted patients who all will deteriorate or die pre-
maturely. Our results emphasize the importance of early diagnosis
and treatment.
We observed rapid and robust neutrophil and platelet engraftment,
which supports other studies of CBT in LDs.4,20 Time to neutrophil
recovery was predicted by higher infused CD341 cell dose and
higher infused TNC, as has been previously reported.4,11,20 In
multivariate analysis of OS, patients who received grafts matched at
5-6/6 HLA loci or who were presymptomatic at time of CBT
experienced improved OS. Conversely, those with poor perfor-
mance status were at higher risk for morbidity (supplemental
Figure 3). Although a recent report described .95% of patients as
alive and engrafted at 8 years after CBT for LSD in specialized
centers,21 these patients all met strict eligibility criteria and received
harmonized conditioning regimens and GVHD prophylaxis. It is
important to acknowledge that our report reflects transplants that
occurred in nearly 30 centers over a timeframe of almost 20 years.
An incompletely understood observation was the higher incidence
of (mainly limited) chronic GVHD in the higher performance status
group of patients. This may be due to the very low number of survivors
in the lowest performance group (only 9 of 29 survived). It is likely that
refinements in patient eligibility and donor selection and improvements
in supportive care that have occurred over the years will translate into
improved outcomes in contemporary patient cohorts.22
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Table 4. Functional outcome descriptives pre-HCT and at most recent follow-up in MLD and GLD patients
Pre-HCT (n 5 113) Most recent follow-up (median 5 87 mo, range: 13-206; n 5 63)
Patient characteristics n (%) Missing Patient characteristics n (%) Missing
Enzyme levels Enzyme levels
MLD (arylsulfatase A) 12 MLD (arylsulfatase A) 11
Low 54 (100) Normal 28 (93.3)
Normal 0 (0)
GLD (galactocerebrosidase) 4 GLD (galactocerebrosidase) 3
Low 43 (100) Normal 18 (94.7)
Normal 0 (0)
Presymptomatic 42 (39.6) 7 Presymptomatic 10 (18.2) 8
Mental development Mental development
Cognitive 40 Cognitive 25
Very low 16 (21.9) Very low 15 (39.5)
Low 18 (24.7) Low 8 (21.0)
Average 34 (46.6) Average 15 (39.5)
Above average 5 (6.8)
Motor 39 Motor 52
Very low 16 (21.6) Very low 10 (90.9)
Low 19 (25.7) Low 0 (0)
Average 34 (45.9) Average 1 (9.1)
Above average 5 (6.8) Above average 0 (0)
Seizures (present) 8 (7.1) 7 Seizures (present) 13 (23.6) 8
Neuropathy 9 Neuropathy 9
Absent 36 (34.6) Stable 37 (68.5)
Mild 28 (26.9) Improved 2 (3.7)
Severe 40 (38.5) Worsened 15 (27.8)
Vision 15 Vision 11
Low 10 (10.2) Stable 47 (90.4)
Blind 2 (2.0) Improved 2 (3.8)
Normal 86 (87.8) Worsened 3 (5.8)
Hearing 14 Hearing 11
Mildly affected 6 (6.1) Stable 48 (92.3)
Severely affected 2 (2.0) Improved 1 (1.9)
Normal 91 (91.9) Worsened 3 (5.9)
School attendance* 9 School attendance* 6
Regular 18 (47.4) Regular 11 (21.6)
Additional support 14 (36.8) Additional support 36 (70.6)
No attendance 6 (15.8) No attendance 4 (7.8)
School performance* 15 School performance* 10
Appropriate for age 25 (75.8) Appropriate for age 15 (35.8)
Lower 8 (24.2) Lower 27 (64.2)
Independence 16 Independence 9
Appropriate for age 52 (53.6) Appropriate for age 15 (27.8)
Needs assistance 45 (46.4) Needs assistance 39 (72.2)
Continence (incontinent) 59 (65.6) 23 Continence (incontinent) 21 (38.9) 9
Gallbladder disease† (present) 9 (27.3) 33 Gallbladder disease† (present) 3 (11.5) 17
*Only for pediatric patients.
†Only for MLD.
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Table 5. Functional outcome descriptives pre-HCT and at most recent follow-up in X-ALD patients
Pre-HCT (n 5 56) Most recent follow-up (median 5 49 mo, range: 25-211; n 5 35)
Patient characteristics n (%) Missing Patient characteristics n (%) Missing
Enzyme levels Enzyme levels
X-ALD (free fatty) 17 X-ALD (free fatty) 18
Normal 0 (0) Normal 1 (5.9)
High/elevated 39 (100) High/elevated 16 (94.1)
Presymptomatic 16 (32.7) 7 Presymptomatic 15 (51.7) 6
Mental development Mental development
Cognitive 18 Cognitive 22
Very low 0 (0) Very low 1 (7.7)
Low 10 (26.3) Low 2 (15.4)
Average 22 (57.9) Average 7 (53.8)
Above average 6 (15.8) Above average 3 (23.1)
Motor 19 Motor 27
Very low 0 (0) Very low 5 (62.5)
Low 10 (27.0) Low 1 (12.5)
Average 21 (56.8) Average 1 (12.5)
Above average 6 (16.2) Above average 1 (12.5)
Seizures (present) 5 (10.2) 7 Seizures (present) 5 (17.9) 7
Neuropathy 9 Neuropathy 8
Absent 31(66.0) Stable 23 (85.2)
Mild 14 (29.8) Improved 1 (3.7)
Severe 2 (4.2) Worsened 3 (11.1)
Vision 7 Vision 5
Low 12 (24.5) Stable 23 (76.7)
Blind 2 (4.1) Improved 1 (3.3)
Normal 35 (71.4) Worsened 6 (20.0)
Hearing 8 Hearing 5
Mildly affected 5 (10.4) Stable 27 (90.0)
Severely affected 2 (4.2) Improved 1 (3.3)
Normal 41 (85.4) Worsened 2 (6.7)
School attendance* 5 School attendance* 6
Regular 35 (79.5) Regular 15 (53.6)
Additional support 7 (15.9) Additional support 9 (32.1)
No attendance 2 (4.6) No attendance 4 (14.3)
School performance* 6 School performance* 6
Appropriate for age 33 (82.5) Appropriate for age 17 (73.9)
Lower 7 (17.5) Lower 6 (26.1)
Independence 14 Independence 10
Appropriate for age 31 (73.8) Appropriate for age 16 (64.0)
Needs assistance 11 (26.2) Needs assistance 9 (36.0)
Continence (incontinent) 4 (10.0) 16 Continence (incontinent) 3 (12.5) 11
Adrenal insufficiency 32 Adrenal insufficiency 8
Absent 4 (16.6) Stable 25 (92.6)
Glucocorticoids 18 (75) Worsened 2 (7.4)
Mineralcorticoids 1 (4.2)
Combined 1 (4.2)
*Only for pediatric patients.
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It has been well described that PS is an important predictor for survival
and late outcomes after HSCT, including CBT.5-8,18,19,23,24 Although
PS is not the ideal tool for assessing neurocognitive development, this
was the best available surrogate of cognitive function for long-term
follow-up. It is important to note that at most recent follow-up, there
were some patients with discrepant PS and neurocognitive scores (ie,
PS . 80, but a low or very low score on mental development, or vice
versa). Nevertheless, PS generally correlated with disease status and
was able to quantify overall well-being that, even if less specific, can
include general characteristics of the disease. Our results also
demonstrated that there was minimal or no decline in PS beyond 1
year after CBT. Notably, presymptomatic disease was correlated with a
higher probability of overall and event-free survival. Combining the PS
before CBT and presymptomatic status could be used as a tool to
predict outcomes. However, prospective studies that include longitu-
dinal assessment of cognitive and motor function along with quality-of-
life measures are warranted.
Moreover, this study emphasizes the importance of presymptomatic
status and short duration from diagnosis to transplant on both early and
late outcomes. These results provide further support that donor cord
blood should be strongly considered when a noncarrier sibling donor is
lacking. Because of the rapid course of these diseases, CB has some
practical advantages above unrelated donors. Although haploidentical
related donors are also readily available, most of these donors will be
disease carriers. Previous studies of HCT in other LSDs have
demonstrated an association between lower enzyme levels and worse
late outcomes.25 Therefore, haploidentical donors are not routinely
recommended for patients with leukodystrophies. Previous studies have
also demonstrated that patients who achieved full-donor chimerism
experienced improved late outcomes.25,26 Although these studies were
conducted in other LSDs, all studies with CB as a donor source in LD
showed high rates of full-donor chimerism.4-6 These results also support
the use of newborn screening (NBS), which allows identification of
neonates eligible for CBT at a time when they still experience maximal
benefit. In select US and EU member states, NBS for GLD or X-
ALD has been or will be implemented in upcoming years.6,27,28
To date, NBS for MLD is not available, but our results, along with
those from other studies, provide evidence that early diagnosis
and transplant prior to onset of symptoms improve early and late
outcomes after CBT.8,9,12,24
This study recognizes that the long-term outcomes of many children are
affected to various extents by their underlying disease, the transplant
procedure, or a combination of both. Although nearly half of the children
in this study were able to perform at an age-appropriate level at school,
many needed additional support services to achieve that level of
performance, especially MLD and GLD patients. Although these results
are better than those of the natural course in nontransplanted
patients,29,30 more research concerning the effects of transplantation
on functional outcomes and quality of life is warranted to optimize late
outcomes, including the quality of life of these patients.
Further research is also needed to better understand the duration
for which CBT can provide a therapeutic effect. It remains unclear
whether the cross-correction of the deficient enzyme after CBT
completely halts disease in MLD and GLD, because significant
posttransplantation peripheral nerve disease has been reported by
others.6,8 Lentiviral haemopoietic stem cell gene therapy that aims
for supranormal enzyme levels may provide a solution for this in the
future, as a recent report suggests for MLD patients. Although
promising, longer follow-up is needed, and only half of patients
achieved supranormal enzyme levels.31
In conclusion, CBT in patients with LD showed promising early and late
outcomes, especially for those who are presymptomatic before CBT
and those who received adequately dosed grafts. Early identification
and treatment appear to be important predictors of outcomes, which
suggests that NBS may further improve outcomes. Furthermore, fast
referral to a specialized center after diagnosis is necessary. For
symptomatic patients transplanted with a low performance score (,60
and 60-80), only 5% and 12%, respectively, of these patients were alive
with improved performance at last known follow-up. Counseling of
these patients and parents is of extreme importance. As life expectancy
for patients with LSDs increases after CBT, international collaboration is
of utmost importance to further optimize therapies, including CBT, to
improve outcomes for these patients. Moreover, prospective trials
comparing new (gene) therapies to the standard therapies are needed.
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